SuperGen’s cancer drug found effective against tumor growth

The data showed that SGI-1252 selectively inhibits wildtype and mutant JAK2 activity in cancer cell lines, resulting in inhibition of STAT5 phosphorylation as well as a reduction in Bcl-XL expression.

SuperGen’s SGI-1252 was also shown to prevent tumor growth in mouse xenograft models. Pharmacokinetic studies indicate that SGI-1252 is orally bioavailable.

James Manuso, president and CEO of SuperGen, said: “We are optimistic that SGI-1252 may be effective in treating leukemia, lymphoma and myeloproliferative disorders and look forward to advancing this promising candidate into the clinic.”